Last updated on September 2020

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028

Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028

Exclusion Criteria:

-Liver and/or heart transplant, or implanted cardiac mechanical assist device

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.